Ignite Creation Date:
2024-05-05 @ 11:56 AM
Last Modification Date:
2024-10-26 @ 9:17 AM
Study NCT ID:
NCT00185588
Status:
COMPLETED
Last Update Posted:
2014-09-15
First Post:
2005-09-12
Brief Title:
Phase 1-2 Vatalanib and Gemcitabine in Advanced Pancreatic Cancer
Sponsor:
George Albert Fisher
Organization:
Stanford University
Study Overview
Official Title:
A Phase 1-2 Study of the VEGF Receptor Tyrosine Kinase Inhibitor PTK787ZK 222584 Vatalanib and Gemcitabine in Patients With Advanced Pancreatic Cancer
Status:
COMPLETED
Status Verified Date:
2014-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of the study is to determine the optimal safe and tolerable dose of gemcitabine in combination with once daily or twice daily dose of PTKZK in patients with unresectable pancreatic cancer The Phase II part of this study planned to determine the antitumor activity of this regimen and its effectiveness of preventing tumor growth and spread
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 95533 | OTHER | None | None |
| PANC0002 | OTHER | OnCore | None |
| CPTK787AUS08 | OTHER | None | None |